U.S. Markets closed

Teva Stock Is Falling Because an Analyst Says the Company Needs ‘Numerous Litigation Wins’

Josh Nathan-Kazis

Bank of America Merrill Lynch analyst Jason Gerberry downgraded the firm to Underperform from Buy, citing risks around the ongoing opioid litigation. He also cut the target price to $9 from $19.